摘要
目的 探讨在精神分裂症患者治疗中分别应用齐拉西酮与利培酮的临床价值。方法 100例精神分裂症患者为研究对象,依据奇偶法分为常规组与实验组,各50例。常规组采用利培酮治疗,实验组采用齐拉西酮治疗。对比两组临床症状评分、临床疗效评分、用药不良反应发生情况。结果 治疗8、12、24周时,两组临床症状评分均低于本组治疗前,且实验组临床症状评分分别为(41.07±3.72)、(32.72±3.79)、(31.04±2.71)分,均低于常规组的(48.21±4.30)、(39.24±5.16)、(35.35±3.50)分,差异均有统计学意义(P<0.05)。治疗8、12周时,实验组临床疗效评分分别为(4.01±0.38)、(2.14±0.52)分,均低于常规组的(4.62±0.54)、(2.73±0.40)分,差异均有统计学意义(P<0.05)。实验组用药不良反应发生率4.0%低于常规组的18.0%,差异有统计学意义(P<0.05)。结论 采用齐拉西酮治疗精神分裂症,可有效改善患者临床症状,且安全性较高,与利培酮对比,近期疗效更显著,适宜临床推广与应用。
Objective To discuss the clinical value of ziprasidone and risperidone in the treatment of schizophrenia. Methods A total of 100 schizophrenic patients were studied and divided into the conventional group and the experimental group according to the parity method, with 50 patients in each group. The conventional group was treated with risperidone, and the experimental group was treated with ziprasidone. The clinical symptom scores, clinical efficacy scores, and occurrence of adverse drug reactions were compared between the two groups.Results At 8, 12 and 24 weeks of treatment, the clinical symptom scores in both groups were lower than those before treatment in this group;the clinical symptom scores of the experimental group were(41.07±3.72),(32.72±3.79) and(31.04±2.71) points, which were lower than(48.21±4.30),(39.24±5.16) and(35.35±3.50) points of the conventional group;all differences were statistically significant(P<0.05). At 8 and 12 weeks of treatment, the clinical efficacy scores of the experimental group were(4.01±0.38) and(2.14±0.52) points,which were lower than(4.62±0.54) and(2.73±0.40) points of the conventional group, and the differences were statistically significant(P<0.05). The incidence of adverse drug reactions in the experimental group was 4.0%,which was lower than 18.0% in the conventional group, and the difference was statistically significant(P<0.05).Conclusion The treatment of schizophrenia with ziprasidone can effectively improve patients’ clinical symptoms and has a higher safety, and its recent efficacy is more significant compared with risperidone, so it is suitable for clinical promotion and application.
作者
田颖
TIAN Ying(Dalian Civil Affairs Service Center(Dalian Social Welfare Institute),Dalian 116013,China)
出处
《中国现代药物应用》
2023年第3期139-141,共3页
Chinese Journal of Modern Drug Application
关键词
精神分裂症
齐拉西酮
利培酮
临床疗效
不良反应
临床症状
Schizophrenia
Ziprasidone
Risperidone
Clinical efficacy
Adverse reactions
Clinical symptoms
